Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cartesian Therapeutics (RNAC) Tax Provisions: 2021-2024

Historic Tax Provisions for Cartesian Therapeutics (RNAC) over the last 4 years, with Dec 2024 value amounting to $287,000.

  • Cartesian Therapeutics' Tax Provisions fell 308.70% to -$288,000 in Q4 2022 from the same period last year, while for Dec 2022 it was $15.4 million, marking a year-over-year change of. This contributed to the annual value of $287,000 for FY2024, which is 101.51% up from last year.
  • According to the latest figures from FY2024, Cartesian Therapeutics' Tax Provisions is $287,000, which was up 101.51% from -$19.0 million recorded in FY2023.
  • In the past 5 years, Cartesian Therapeutics' Tax Provisions ranged from a high of $16.0 million in FY2021 and a low of -$19.0 million during FY2023.
  • Over the past 3 years, Cartesian Therapeutics' median Tax Provisions value was -$609,000 (recorded in 2022), while the average stood at -$6.4 million.
  • Per our database at Business Quant, Cartesian Therapeutics' Tax Provisions plummeted by 3,019.87% in 2023 and then skyrocketed by 101.51% in 2024.
  • Over the past 4 years, Cartesian Therapeutics' Tax Provisions (Yearly) stood at $16.0 million in 2021, then slumped by 103.81% to -$609,000 in 2022, then plummeted by 3,019.87% to -$19.0 million in 2023, then soared by 101.51% to $287,000 in 2024.